The Investigator Meeting for GH56 trial was Held Successfully

Genhouse Bio (Suzhou) Co., Ltd. recently successfully hosted the investigator meeting for GH56 (PRMT5) clinical trial. Over ten investigators from all the study centers and the project team of Genhouse participated in the meeting. They conducted in-depth discussions on the product's characteristics and advantages, clinical data, and the implementation and strategies of the clinical trial protocol in a hybrid format combining both online and offline participation.

Professor Li Ning from the Chinese Academy of Medical Sciences Cancer Hospital, as the leading investigator of the project, delivered the opening remarks. During the subsequent data analysis and discussion, Professor Li pointed out that GH56 has demonstrated clinical efficacy at a relatively low starting dose level. All patients enrolled in the lower dose groups showed disease control in their first efficacy assessment after treatment, which significantly boosted confidence in the study. The attending investigators expressed their commitment to close collaboration and thorough communication, aiming to ensure that the subjects can fully benefit from the innovative therapeutic agent through effective clinical translation. The meeting also included in-depth discussions on the details of the clinical trial protocol, such as the patient population, and the next steps in the study operation, providing a solid foundation for the smooth and successful conduct of the trial.

Dr. Miao Huilei from the Chinese Academy of Medical Sciences Cancer Hospital and Director Li Shuang from the Shanghai GoBroad Cancer Hospital shared their experiences in subject communication, screening and management, providing valuable references and insights for future.

Dr. Wang Kuifeng, the Chairman of Genhouse Bio, reviewed the company's R&D journey and introduced its current pipelines. The preclinical data of GH56 capsules have already demonstrated differentiated advantages, and the clinical data obtained so far have also confirmed the product's initial efficacy and good safety profile. In the current environment where the challenges of pharmaceutical R&D have increased, he stated that Genhouse will actively promote the development of this product, quickly advance it into the pivotal clinical study, and accelerate the new drug's launch process, bringing new hope to patients with advanced solid tumors.

In his concluding remarks, Professor Li from the Chinese Academy of Medical Sciences Cancer Hospital highlighted that the positive response of GH56 capsules in patients with advanced solid tumors and MTAP deficiency is very encouraging. He also commended the outstanding performance of the research teams at various centers in the earlier stages. He looks forward to the close collaboration among all research centers in the future to achieve high-quality and efficient advancement of the clinical trial.

The successful convening of the GH56 project investigator meeting demonstrates Genhouse’s R&D strength and innovation capabilities in the field of synthetic lethality. It also lays the foundation for the subsequent progress of the project, clarifies the path and objectives. Genhouse will complete the clinical trial to high-quality standards with high efficiency, and with the expectation of bringing breakthrough therapeutic solutions to more patients as soon as possible.

About GH56

GH56 is a novel MTA-Cooperative PRMT5 inhibitor that can exert synthetic lethality in tumors with methionine adenosine triphosphate (MTAP) deficiency. MTAP, as a tumor suppressor gene, is absent in approximately 10-15% of all tumors. Particularly in gliomas, more than 40% of cases exhibit MTAP deficiency. The absence of MTAP leads to the accumulation of its substrate, methionine adenosine triphosphate (MTA). MTA binds to PRMT5 to form the PRMT5-MTA complex, which inhibits the activity of PRMT5. Targeting the PRMT5-MTA complex in MTAP-deficient tumors has the potential to kill cancer cells while minimizing the impact on normal cells, thereby achieving a larger therapeutic window. GH56's excellent safety profile and high brain penetration capability hold significant clinical value for this target.

About Genhouse Bio

Genhouse Bio (Suzhou) Co., Ltd., as an AI-driven biotech company, focuses on the development of globally leading targeted anti-tumor small molecule drugs. The company closely follows a process-oriented and modular innovative drug research and development system, fully relying on AI empowerment. Based on the pioneering concept of “AI/Biology-Driven Smart Design” in drug development, Genhouse has established a self-sustaining and innovative integrated technology platform: Structural Biology Platform, Drug Discovery and Design Platform, Drugability Evaluation Platform, and Translational Medicine Platform. The company is deeply involved in the Ras-MAPK signaling pathway (Pipeline 1.0) and the field of synthetic lethality (Pipeline 2.0), forming product pipelines centered on targeted anti-tumor drugs.